艾美无血清狂苗获受理上市注册,迭代大单品驱动业绩增长

中国网财经
08 Apr

疫苗龙头企业艾美疫苗4月7日公告,公司研发的无血清迭代狂犬疫苗上市注册获国家药监局出具的《受理通知书》。此外,该疫苗已获得相应的产品生产许可证。目前,全球市场上尚未有无血清狂犬疫苗获批上市,该产品有望成为首个上市产品,标志着艾美疫苗已取得重大技术突破,进一步巩固了其在狂犬疫苗领域的全球领先地位。复星国际证券在4月3日发布的研报中指出:艾美疫苗的迭代管线驱动价值增长。包括无血清狂犬疫苗在内的3款产品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10